| 1 | A51 EFFECT OF LYOPHILIZED STERILE FECAL FILTRATE VS LYOPHILI… (10.1093/jcag/gwz006.050) | Abstract References ORCID | 111.85 | 30 |
| 2 | A29 THE RISING PREVALENCE OF INFLAMMATORY BOWEL DISEASE IN C… (10.1093/jcag/gwy009.029) | Abstract References ORCID License | 111.39 | 12 |
| 3 | A109 PREGNANCY OUTCOMES IN WOMEN EXPOSED TO USTEKINUMAB IN T… (10.1093/jcag/gwy009.109) | Abstract References ORCID License | 111.39 | 12 |
| 4 | Canadian Association of Gastroenterology Clinical Practice G… (10.1093/jcag/gwy071) | Abstract ORCID | 108.37 | 146 |
| 5 | A36 THE GLOBAL INCIDENCE OF PEPTIC ULCER DISEASE AND ITS COM… (10.1093/jcag/gwy009.036) | Abstract References ORCID License | 104.14 | 10 |
| 6 | A90 THREE PATIENTS WITH INFLAMMATORY BOWEL DISEASE DIAGNOSED… (10.1093/jcag/gwy009.090) | Abstract References ORCID License | 104.14 | 10 |
| 7 | A198 PHARMACODYNAMIC EFFECTS OF THE ORAL, NON-STEROIDAL FARN… (10.1093/jcag/gwy008.199) | Abstract References ORCID License | 95.42 | 8 |
| 8 | A266 HEPATOCELLULAR CARCINOMA PREVALENCE IN NON-CIRRHOTIC HE… (10.1093/jcag/gwy009.266) | Abstract References ORCID License | 90.31 | 7 |
| 9 | Clinical Practice Guidelines for the Assessment of Uninvesti… (10.1093/jcag/gwx008) | Abstract ORCID | 85.80 | 51 |
| 10 | A210 NEONATAL INFLAMMATORY SKIN AND BOWEL DISEASE CAUSED BY… (10.1093/jcag/gwy008.211) | Abstract References ORCID License | 84.51 | 6 |
| 11 | Predictors of Cesarean Delivery in Pregnant Women with Infla… (10.1093/jcag/gwy003) | Abstract ORCID | 73.12 | 28 |
| 12 | A195 TRIPLE OVERLAP SYNDROME? A RARE CASE OF AIH, PBC AND PS… (10.1093/jcag/gwy009.195) | Abstract References ORCID License | 69.90 | 4 |
| 13 | Transient Elastography in the Evaluation of Cystic Fibrosis–… (10.1093/jcag/gwy029) | Abstract ORCID | 69.90 | 24 |
| 14 | Canadian Association of Gastroenterology Position Statement… (10.1093/jcag/gwx002) | Abstract ORCID | 65.05 | 19 |
| 15 | Canadian Association of Gastroenterology Position Statement:… (10.1093/jcag/gwy064) | Abstract ORCID | 65.05 | 19 |
| 16 | A160 ESTIMATION OF FIBROSIS PROGRESSION RATES FOR CHRONIC HE… (10.1093/jcag/gwy008.161) | Abstract References ORCID License | 60.21 | 3 |
| 17 | A222 INCREASING PREVALENCE OF CIRRHOSIS IN ONTARIO OVER THE… (10.1093/jcag/gwy008.223) | Abstract References ORCID License | 60.21 | 3 |
| 18 | A303 SIMULTANEOUS PRESSURE WAVES ARE A KEY COMPONENT OF HUMA… (10.1093/jcag/gwy008.304) | Abstract References ORCID License | 60.21 | 3 |
| 19 | A127 ANTI-TNF VS SURGICAL MANAGEMENT OF ABDOMINAL PHLEGMON I… (10.1093/jcag/gwy009.127) | Abstract References ORCID License | 60.21 | 3 |
| 20 | A132 DEVELOPMENT OF THE TUMMY-CD, A SYMPTOMS-BASED DISEASE A… (10.1093/jcag/gwy009.132) | Abstract References ORCID License | 60.21 | 3 |
| 21 | A157 THE THRESHOLD FOR INFLIXIMAB TROUGH LEVELS LEADING TO D… (10.1093/jcag/gwy009.157) | Abstract References ORCID License | 60.21 | 3 |
| 22 | A169 EFFICACY AND SAFETY OF ELUXADOLINE IN ELDERLY PATIENTS… (10.1093/jcag/gwy009.169) | Abstract References ORCID License | 60.21 | 3 |
| 23 | Improving Access to Gastroenterologist Using eConsultation:… (10.1093/jcag/gwy017) | Abstract ORCID | 60.21 | 15 |
| 24 | OUP accepted manuscript (10.1093/jcag/gwz016) | Abstract References ORCID License | 60.21 | 3 |
| 25 | The Benefit of Fentanyl in Effective Sedation and Quality of… (10.1093/jcag/gwy041) | Abstract ORCID | 58.80 | 14 |
| 26 | A256 GLOBAL INCIDENCE OF ACUTE PANCREATITIS THROUGH TIME: A… (10.1093/jcag/gwz006.255) | Abstract References ORCID | 58.36 | 5 |
| 27 | Rectal Indomethacin Prevents Moderate to Severe Post-ERCP Pa… (10.1093/jcag/gwy006) | Abstract ORCID | 57.31 | 13 |
| 28 | Real World Effectiveness of Golimumab Therapy in Ulcerative… (10.1093/jcag/gwy019) | Abstract ORCID | 55.70 | 12 |
| 29 | Clinical Practice Guideline for the Medical Management of Pe… (10.1093/jcag/gwy047) | Abstract ORCID | 55.70 | 12 |
| 30 | Diffuse Esophageal Narrowing in Eosinophilic Esophagitis: A… (10.1093/jcag/gwy022) | Abstract ORCID | 53.96 | 11 |
| 31 | A257 ASSOCIATION BETWEEN CELIAC DISEASE AND AUTISM SPECTRUM… (10.1093/jcag/gwz006.256) | Abstract References ORCID | 52.42 | 4 |
| 32 | A17 EFFICACY AND SAFETY OF FILGOTINIB AS MAINTENANCE THERAPY… (10.1093/jcag/gwab002.016) | References ORCID | 52.07 | 10 |
| 33 | The Use of Standardized Questions in Identifying Patients wi… (10.1093/jcag/gwy010) | Abstract ORCID | 52.07 | 10 |
| 34 | Addressing Mental Health in Persons with IBD (10.1093/jcag/gwy038) | Abstract ORCID | 52.07 | 10 |
| 35 | The Impact of Inflammatory Bowel Disease in Canada 2018: Chi… (10.1093/jcag/gwy056) | Abstract | 51.52 | 114 |
| 36 | The Impact of Inflammatory Bowel Disease in Canada 2018: Epi… (10.1093/jcag/gwy054) | Abstract | 51.42 | 113 |
| 37 | The Impact of Inflammatory Bowel Disease in Canada 2018: Qua… (10.1093/jcag/gwy048) | Abstract | 49.09 | 91 |
| 38 | A6 PREFERENCES FOR CARE FOR ACTIVE SYMPTOMS OF IBD IN A POPU… (10.1093/jcag/gwy008.007) | Abstract References ORCID License | 47.71 | 2 |
| 39 | A9 SHORT-TERM EXPOSURE TO A HIGH SUGAR DIET REDUCES SHORT CH… (10.1093/jcag/gwy008.010) | Abstract References ORCID License | 47.71 | 2 |
| 40 | A25 HOME EXERCISE THERAPY IS WELL TOLERATED AND IMPROVES EXE… (10.1093/jcag/gwy008.026) | Abstract References ORCID License | 47.71 | 2 |
| 41 | A34 DARATUMUMAB DOSE DEPENDENT LIVER INJURY (10.1093/jcag/gwy008.035) | Abstract References ORCID License | 47.71 | 2 |
| 42 | A58 PATIENT SATISFACTION WITH ENDOSCOPY UNITS: THE EDMONTON… (10.1093/jcag/gwy008.059) | Abstract References ORCID License | 47.71 | 2 |
| 43 | A85 EFFICACY AND SAFETY OF DOSE ADJUSTMENT AND DELAYED RESPO… (10.1093/jcag/gwy008.086) | Abstract References ORCID License | 47.71 | 2 |
| 44 | A107 POSTOPERATIVE OUTCOMES AMONG USTEKINUMAB TREATED CROHN’… (10.1093/jcag/gwy008.108) | Abstract References ORCID License | 47.71 | 2 |
| 45 | A130 TABLEAU DASHBOARD AS A QUALITY IMPROVEMENT AND STRATEGI… (10.1093/jcag/gwy008.131) | Abstract References ORCID License | 47.71 | 2 |
| 46 | A153 MEASURING QUALITY OF LIFE AND DISEASE ACTIVITY IN PEDIA… (10.1093/jcag/gwy008.154) | Abstract References ORCID License | 47.71 | 2 |
| 47 | A203 ACTIVITY OF MBX-8025, A POTENT AND SELECTIVE PPAR-δ AGO… (10.1093/jcag/gwy008.204) | Abstract References ORCID License | 47.71 | 2 |
| 48 | A242 THE P2 ISOFORM CLASS OF THE TRANSCRIPTION FACTOR HNF4A… (10.1093/jcag/gwy008.243) | Abstract References ORCID License | 47.71 | 2 |
| 49 | A301 GUT MICROBIOTA FROM A PATIENT WITH GENERALIZED ANXIETY… (10.1093/jcag/gwy008.302) | Abstract References ORCID License | 47.71 | 2 |
| 50 | A22 A HIDDEN CAUSE OF DRUG-INDUCED LIVER FAILURE (10.1093/jcag/gwy009.022) | Abstract References ORCID License | 47.71 | 2 |